Mr. Thompson joined the Questcor Board of Directors in January 1996. Mr. Thompson was President, Chief Executive Officer and a Director of Angstrom Pharmaceuticals, Inc., from November 2002 through June 2007. From September 2000 until August 2002, he was President, Chief Executive Officer and a director of Chimeric Therapies, Inc. From May 1999 until September 2000, he was President, Chief Operating Officer and a director of Bio-Technology General Corporation, a pharmaceutical company. From January 1996 to May 1999, he was President and Chief Executive Officer and a director of Cytel Corporation, a biopharmaceutical company. Mr. Thompson is also a director of Aradigm Corporation and Savient Pharmaceuticals, Inc. Mr. Thompson holds a B.S in pharmacy from Kansas University and a J.D. from The George Washington University School of Law.
Mr. Bailey joined Questcor in May 2007 as Interim President, and was appointed to his current position in November 2007. Mr. Bailey joined Questcor's Board of Directors in May 2006. Mr. Bailey is currently the non-executive Chairman of the Board of STAAR Surgical Company, a leader in the development, manufacture, and marketing of minimally invasive ophthalmic products employing proprietary technologies. Mr. Bailey served as Chairman of the Board of Comarco, Inc., a provider of wireless test products for the wireless industry and a maker of emergency call box systems and mobile power products for handheld devices from 1998 to August 2007. He also served from June 1990 to April 2000 as President and Chief Executive Officer of Comarco, Inc., where he was employed since May 1980. He earned a B.S. in Mechanical Engineering from the Drexel Institute of Technology in 1968, an M.S. Degree in Operations Research from the University of Southern California in 1971 and an M.B.A. from Pepperdine University in 1986.
Dr. Blutt joined the Company�s Board of Directors in July 2010. Dr. Blutt, 53, is currently the Founder and Chief Executive Office of Consonance Capital, a New York based investment firm that is a shareholder of Questcor. Prior to founding Consonance Capital in 2004, Dr. Blutt was Executive Partner at JP Morgan Partners, a multi-billion-dollar global investment fund, and was responsible for locating, structuring, negotiating and financing acquisitions, private equity and venture capital transactions, primarily in the healthcare industry. Dr. Blutt has served on the boards of over thirty healthcare companies, including Cardinal Health, Fisher Scientific, and Somerset Pharmaceuticals. Dr. Blutt earned his Bachelor of Arts and Doctor of Medicine degrees from the University of Pennsylvania and his Masters of Business Administration from The Wharton School at the University of Pennsylvania. Dr. Blutt completed his residency in Internal Medicine at The New York Hospital/Cornell Medical Center. Dr. Blutt is also board-certified in Internal Medicine and a Clinical Assistant Professor of Medicine at Weill Cornell Medical College.
Mr. Bradsher, joined the Company's Board of Directors in March, 2004. Since 2002, Mr. Bradsher has been President of Broadwood Capital, Inc., a private investment firm. Previously, he was a Managing Director at Whitehall Asset Management, Inc. from 1999 to 2002. From 1994 to 1999, he was a Managing Director, and from 1995 to 1999 also Chief Operating Officer, of Campbell Advisors, Inc., an investment management firm. Prior to that, he was a healthcare equity analyst at investment banking firms Alex. Brown & Sons Incorporated and Hambrecht & Quist Incorporated. Mr. Bradsher holds a BA in Economics from Yale College and is a Chartered Financial Analyst.
Stephen C. Farrell joined the Company's Board of Directors in November 2007. Mr. Farrell served as President of PolyMedica Corporation until November 2007 after PolyMedica was acquired by Medco Health Solutions, the nation's largest pharmacy benefit manager, in a transaction valued at $1.5 billion. PolyMedica is a leading direct-to-consumer provider of health care products and services for individuals with chronic diseases, and is best known for its Liberty Medical brand. During his eight year tenure at PolyMedica, Mr. Farrell served as President, Chief Operating Officer, Chief Financial Officer, Chief Compliance Officer, and Treasurer. Earlier in his career, Mr. Farrell served as Senior Manager at PriceWaterhouseCoopers LLP. Mr. Farrell holds an A.B. from Harvard University, and an M.B.A. from the University of Virginia. Mr. Farrell is also a certified public accountant.
Mr. Silverman joined the Company's Board of Directors in December, 2009. Mr. Silverman, 51 is currently Chief Executive Officer of privately-held Marina Medical Billing Service Inc. based in Cerritos, CA, a company focused on providing revenue cycle management services to emergency room physicians nationally. Prior to joining Marina Medical in August of 2009, Mr. Silverman was President and Chief Executive Officer of LifeComm, Inc., a Qualcomm Incorporated incubated wireless health services start-up. Prior to Lifecomm, Mr. Silverman had a very successful eight-year tenure as President and Chief Executive Officer of Quality Systems Inc., where he led the developer of medical and dental practice management software to 600% organic revenue growth and an increase in market value from $42 million to $1.2 billion. Previously, Mr. Silverman was the Chief Operations Officer of Corvel Corporation. He earned a Bachelor of Arts degree from Amherst College and a Masters in Business Administration from Harvard Graduate School of Business Administration.
Dr. Whitcup is the Executive Vice President, R&D and Chief Scientific Officer at Allergan. Previously, Dr. Whitcup was Senior Vice President and Head of the Ophthalmology Therapeutic Area at Allergan. He is on the faculty at the Jules Stein Eye Institute/David Geffen School of Medicine at UCLA and also serves as a Director on the Board of Avanir Pharmaceuticals and as a member of the Biology Chair's Council at Caltech.
Dr. Whitcup graduated from Cornell University Medical College and completed residency training both in internal medicine at UCLA Medical Center and in ophthalmology at the Massachusetts Eye and Ear Infirmary-Harvard Medical School. He then received fellowship training in uveitis and ocular immunology at the National Eye Institute at the National Institutes of Health. Prior to coming to Allergan, Dr. Whitcup was Clinical Director of the National Eye Institute, and also served as head of the Clinical Branch and Director of the uveitis and ocular immunology fellowship program. Dr. Whitcup also served as Chair of the NIH Medical Executive Committee.
Dr. Whitcup currently directs Allergan's drug discovery efforts, medical device research, and the worldwide clinical development programs that include ophthalmology, neurosciences, dermatology, plastic surgery, obesity, and urology. He is also in charge of Allergan's global medical affairs organization. Dr. Whitcup's laboratory work has focused on inflammatory disease and the role of cell adhesion molecules in the pathogenesis of autoimmune disease. Dr. Whitcup is an author on over 150 scientific articles, book chapters, and a textbook on ocular inflammatory disease. Dr. Whitcup has been the recipient of numerous awards including the Cogan Award from the Association for Research in Vision and Ophthalmology (ARVO).